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Abstract
Background: Menstrual Toxic Shock Syndrome (mTSS) is thought to be associated with the vaginal colonization
with specific strains of Staphylococcus aureus TSST-1 in women who lack sufficient antibody titers to this toxin.
There are no published studies that examine the seroconversion in women with various colonization patterns of
this organism. Thus, the aim of this study was to evaluate the persistence of Staphylococcus aureus colonization at
three body sites (vagina, nares, and anus) and serum antibody to toxic shock syndrome toxin-producing
Staphylococcus aureus among a small group of healthy, menstruating women evaluated previously in a larger
study.
Methods: One year after the completion of that study, 311 subjects were recalled into 5 groups. Four samples
were obtained from each participant at several visits over an additional 6-11 month period: 1) an anterior nares
swab; 2) an anal swab; 3) a vagina swab; and 4) a blood sample. Gram stain, a catalase test, and a rapid S. aureus-
specific latex agglutination test were performed to phenotypically identify S. aureus from sample swabs. A
competitive ELISA was used to quantify TSST-1 production. Human TSST-1 IgG antibodies were determined from
the blood samples using a sandwich ELISA method.
Results: We found only 41% of toxigenic S. aureus and 35.5% of non-toxigenic nasal carriage could be classified as
persistent. None of the toxigenic S. aureus vaginal or anal carriage could be classified as persistent. Despite the low
persistence of S. aureus colonization, subjects colonized with a toxigenic strain were found to display distributions
of antibody titers skewed toward higher titers than other subjects. Seven percent (5/75) of subjects became
seropositive during recall, but none experienced toxic shock syndrome-like symptoms.
Conclusions: Nasal carriage of S. aureus appears to be persistent and the best predicator of subsequent
colonization, whereas vaginal and anal carriage appear to be more transient. From these findings, it appears that
antibody titers in women found to be colonized with toxigenic S. aureus remained skewed toward higher titers
whether or not the colonies were found to be persistent or transient in nature. This suggests that colonization at
some point in time is sufficient to elevate antibody titer levels and those levels appear to be persistent. Results also
indicate that women can become seropositive without experiencing signs or symptoms of toxic shock syndrome.
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T o x i cs h o c ks y n d r o m e( T S S )i sas y s t e m i cd i s e a s eo f
acute onset characterized by fever, hypotension, myalgia,
rash, multiple-organ failure, and late desquamation of
hands and feet [1]. It is associated with colonization
with toxic shock syndrome toxin-1 (TSST-1)-producing
S. aureus in the vagina during menstruation, or at other
sites due to complications of a staphylococcal infection
(especially skin or respiratory tract), or as a complica-
tion of a surgical procedure or other medical condition
[2,3]. TSST-1, the most common such toxin, causes the
vast majority (95%) of cases associated with menstrua-
tion and 40-60% of the nonmenstrual cases [4,5].
Menstrual Toxic Shock Syndrome (mTSS) has been
associated with menstruation and tampon use. Despite
the very low incidence of mTSS, the disease remains of
interest, because tampons are widely used. Czerwicnski
[6] reported in a recent descriptive research study that
approximately 80% of the study participants (women
under of the age of 41 from California) used tampons at
some point during menstruation. It has also been
reported recently that about 70% of women in the Uni-
ted States of America (USA), Canada and much of Wes-
tern Europe use tampons at some point during
menstruation [7].
Menstrual TSS is generally thought to be caused by
S. aureus TSST-1 in a susceptible host [8,9]. TSST-1 is
considered a superantigen (SAg), a class of very potent
immune stimulators that interact with the immune sys-
tem in a way that is different from conventional anti-
gens. As a result, the magnitude of immune stimulation
by a SAg is usually 10-500,000 fold higher than with
convention antigens. This exaggerated release of inflam-
matory cytokines is responsible for the clinical signs of
illness associated with these toxins [10,11]. Individuals
who lack neutralizing antibodies to a SAg are at a
higher risk of developing severe systemic disease with
hypotension and organ failure, particularly if they hap-
pen to be high responders to these specific SAgs
[11-13].
Four factors are thought to be required for the devel-
opment of the mTSS: (1) vaginal colonization with a
toxigenic strain of S. aureus; (2) production of TSST-1;
(3) penetration of a sufficient concentration of TSST-1
across the epithelium to cause the disease; and (4)
absence or insufficient titers of neutralizing antibody to
the toxin. Vaginal colonization by toxigenic S. aureus
has been reported in 1% to 4% of the populations
studied [[14-18]; ParsonnetJ ,T o s t e s o nA ,M o d e r nP ,
Wissemann K. Wissemann: Abstr. 33
rd Intersci. Conf.
Antimicrob. Agents Chemother. abstr. 1327, 1993]. In-
vitro studies have shown that the production of TSST-1
by toxigenic S. aureus is dependent on environmental
factors such as the partial pressure of O2 and CO2 [19],
as well as other factors such as iron concentration, pH
and temperature [20-22]. Once produced, TSST-1 must
then penetrate the vaginal mucosal surface. It has been
shown that topical exposure to this superantigen in an
ex vivo model causes an increase in mucosal permeabil-
ity in a non-dose-dependent manner [23]. If TSST-1 is
capable of penetrating the epithelial surfaces, it can be
neutralized effectively by anti-TSST-1 antibodies [24].
Bergdoll has shown that individuals who have developed
TSS tend to have lower sera antibody titers to TSST-1
than healthy individuals [8]. Studies have also shown
that sera antibody titers increase with age [25], and that
the vast majority (87-100%) of the adult population has
developed sera antibody to TSST-1 [[14,15,26,25];
Vergeront JM, Blouse LE, Crass, BA, Stolz SJ, Bergdoll
M S ,D a v i sJ P :A b s t r .I n t e r s c i .C o n f .A n t i m i c r o b .A g e n t s
Chemother, abstr. 610, 1984].
Results from our previous prevalence study of 3012
healthy, menstruating women [14] supported our
hypothesis that the low incidence of mTSS is a result of
two factors: 1) the majority of women colonized with S.
aureus are colonized by non-toxigenic strains, and 2)
most women have positive antibody titers to TSST-1.
We found 75% of S. aureus carriers (or 20% of the
population) were colonized with non-toxigenic S. aureus
and only 1% of the study population was colonized vag-
inally with toxigenic strains of S. aureus. Positive anti-
body prevalence, defined as titer ≥1:32, was high in the
general study population (85%), and even higher among
subjects colonized by toxigenic S. aureus in the nose
(98%), vagina (97%), or anus (100%). Only eight percent
(8%) of the study population were classified as antibody
“negative,” exhibiting antibody titer ≤1:4.
This follow up study was designed to determine the
persistence of S. aureus and serum antibody among
groups of menstruating women recalled from the pre-
vious study. Negative controls for S. aureus and serum
antibody were included to determine whether subjects
became S. aureus carriers or seroconverted during recall.
Previous studies in this area have focused on the persis-
tence of nasal carriage of S. aureus among different
p o p u l a t i o n s[ 2 7 - 2 9 ] ,a sw e l la st h ec l a s s i f i c a t i o n[ 2 7 ] ,
and prediction [30,31] of nasal carrier states. To our
knowledge, this is the first published study to evaluate
the persistence of serum antibody and S. aureus carriage
at two additional body sites (anus and vagina).
Methods
Subjects
Approximately one year after completion of the previous
study of 3012 subjects, published in 2005 by Parsonnet,
et al., [14] subjects, a smaller subgroup was recalled and
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Page 2 of 8followed for an additional 6-11 months, depending upon
the group assignment (Table 1). Groups consisted of
both vaginal and non-vaginal carriers of toxigenic
TSST-1 - producing S. aureus, carriers of non-toxigenic
S. aureus and two control groups: non-carriers of
S. aureus and subjects who were antibody negative.
Groups 3-5 were scheduled for three equally spaced
visits. Groups 1 and 2 were scheduled for four equally
spaced visits because of our interest in toxigenic
S. aureus colonization. Subjects were recalled from five
geographically separate sites in North America by Hill
Top Research Inc. in Cincinnati, OH; East Brunswick, NJ;
St. Petersburg, FL; Scottsdale, AZ and Winnipeg, Mani-
toba, Canada. Recall was based on a target enrollment of
75 participants in Groups 2-5. Target enrollment for
Group 1 was the total number of subjects that met the
criteria (n = 33). The total number of subjects who met
the Group 1 criteria (S. aureus TSST-1 vaginal carriers)
from the previous study was very low (33 subjects/3012
total subjects). Every attempt was made to recruit all
Group 1 subjects. Some of the subjects could not be
located and others did not wish to participate in this
follow up study.
Women were eligible for enrollment in this study if
they completed the previous study and continued to
meet the original enrollment criteria [14] on recall.
Briefly, the criteria required subjects to be between the
ages of 13-40, to be in good health, to have regular
menstrual cycles (length between 21 and 35 days), to
use tampons at least occasionally, and to have refrained
from bathing or other activities which could alter the
vaginal environment within the 2 hours prior to their
scheduled visit (Table 2).
S u b j e c t sr e a da n ds i g n e dar e v i s e di n f o r m e dc o n s e n t
document prior to the collection of any information or
clinical sampling. Subjects were removed from the study
if they failed to meet the inclusion criteria and satisfied
any of the exclusion criteria at any time during the
study.
Study conduct
Study protocol and informed consent document were
reviewed and approved by Hill Top’s Institutional
Review Board. Informed consent was obtained from all
subjects participating in the previous prevalence study.
This follow up study was conducted from February, 29,
2000 to March 29, 2001.
Procedures, methods and materials used in this study
were identical to those used in the previously published
study [14]. Procedures and methods are summarized in
the following sections.
Sample collection
Trained personnel at each recruitment site collected the
following samples from each subject: 1) an anterior
nares swab (penetration of 0.5-1.0 inch); 2) an anal swab
(approximately 0.5 to 1 inch past the anal sphincter); 3)
a midpoint vagina swab (approximately 3 - 4 inches into
the vagina) and 4) a blood sample.
Sample Handling
Swabs (nasal, anal and vaginal) were shipped overnight
to Harvard Medical School, Channing Laboratory (Bos-
ton, MA) for isolation and phenotypic identification of
S. aureus and TSST-1 production. Collected serum was
shipped overnight to Dartmouth-Hitchcock Medical
Center (Lebanon, NH) for analysis of TSST-1 antibo-
dies. Clinical laboratories were supplied with subject
number, subject’s initials and area of the body sampled.
Swab analyses
Using standard, published phenotypic methods for isola-
tion of S. aureus from human samples, [14,32,33] nasal
and anal swabs were streaked onto a mannitol salt agar
(MSA) plate, vaginal swabs were dispersed into Amies
medium with agar, streaked onto a MSA plate, incu-
bated for 48 hrs and visualized for characteristic mor-
phology of S. aureus. Colonies were enumerated,
isolated onto plates containing trypticase soy agar with
Table 1 Description of subject groups enrolled in follow up study
Group
No.
Description Body site where
S. aureus detected
in Parsonnet 2005
study
a
Ab present in
Parsonnet 2005
study
b
No. of subjects
enrolled
c
No. of subjects
completing all
visits
1 Carriers of SA TSST-1(+) Vagina Yes or No 14 11
2 Carriers of SA TSST-1(+) Nose or anus Yes 78 64
3 Carriers of SA TSST-1(-) Any site Yes 69 49
4 Non-carriers None Yes 75 58
5 Negative Ab control
(Carriers or Non-carriers)
Any site No 75 61
aBody sites sampled & found positive = vagina, nose and anus.
bYes = anti-TSST-1 antibody titers ≥ 1:32; No = anti-TSST-1 titers ≤ 1:4.
c Subjects who returned for at least one visit during follow up.
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Page 3 of 85% sheep blood, and incubated for 24 hrs. Gram stain, a
catalase test, and a rapid S. aureus-specific latex aggluti-
nation test were performed to phenotypically identify S.
aureus.
Determination of TSST-1 production
A previously validated and published competitive ELISA
was used to quantify TSST-1 production using a mem-
brane over agar protocol with subsequent TSST-1 quan-
tification by ELISA [14,32,34]. After being positively
identified as S. aureus, a heavy suspension was devel-
oped in PBS and 200 ul of the suspensions was placed
on a dialysis membrane covering a 60 × 15 mm Brain
Heart Infusion Petri plate. The plates were incubated in
a humid chamber at 37 deg C for 24 h, washed with 1.5
mL of PBS and collected by centrifugation. Historical
samples of S. aureus that were known not to produce
T S S T - 1a n do t h e r st h a tp r o d u c e dT S S T - 1s e r v e da s
negative and positive controls, respectively. All S. aureus
strains isolated at the Channing Laboratory were
shipped to Dartmouth-Hitchcock Medical Center for
confirmatory analyses using ELISA and/or PCR techni-
ques [35].
Serum analyses
An indirect antibody capture assay was used to deter-
mine the serum anti-TSST-1 IgG antibody titer of each
subject. This method was used in the large seropreva-
lence study published by Parsonnet, et al., in 2005 [14].
Briefly, non-immune human serum from healthy volun-
teers and Human Immune Glogulin Intravenous IgG
served as negative and positive controls, respectively.
Microtiter plates coated with TSST-1 (0.5 μg/mL) and
sera were diluted serially in phosphate buffered saline,
incubated overnight, treated with goat anti-human IgG/
alkaline phosphatase, incubated, washed, and then
treated with an enzyme substrate [1 mg/mL p-nitrophe-
nyl phosphate in 10% diethanolamine buffer]. Plates
were incubated at 24°C until positive control wells
reached an optical density (OD) of 1.0 (405 nm). The
OD of sample solutions was determined and dilution
curves were plotted for each sample. The threshold OD
was determined previously by testing sera from patients
with TSS caused by TSST-1. All such sera (diluted 1:4)
yielded an OD of less than 0.2 times that of the positive
control.
The antibody titer of each sample was calculated as
the highest dilution yielding an OD greater than that of
the positive control. Samples with titers of ≤ 1:4 were
classified as being “negative” for antibody and those
with titers of ≥ 1:32 were classified as “positive.” These
classifications are based on previous clinical experience
with several hundred patients with either mTSS or
TSST-1-induced nonmenstrual TSS. Of these patients,
greater than 90% had a titer of ≤1:4 and 100% had a
titer of < 1:32 (Parsonnet, unpublished observations).
Titers of 1:8 and 1:16 were classified as “intermediate”
(i.e., likely to contain antibodies to TSST-1, but may not
be associated with protection from mTSS). Dilution
curves were scrutinized by two observers, with concor-
dance required for there to be a final antibody determi-
nation. Because the assay yielded a quantitative result
(not subject to observer bias), there was no inter- or
intra-observer variation in the antibody result.
Classification of S. aureus carriage
Carriage was classified as transient, intermittent or per-
sistent based on calculations of carrier index in order to
compare results to others in the literature [27]. Subjects
were included if they had completed a minimum of
three post initial visits. The carrier index (CI) was calcu-
lated as the number of swabs with positive culture of
Table 2 Inclusion/Exclusion Criteria for the previous and this follow up study
Inclusion Exclusion
Had a regular menstrual cycles (minimum of 21 days
and maximum of 35 days);
Had participated in another clinical study
Had used tampons at least occasionally Were pregnant, actively trying to get pregnant or
suspected they were pregnant
Refrained taking a bathe or shower within the 2 hours
prior to their scheduled visits
Had a gynecological abnormality as judged by the
study medical personnel
Refrained from using douching substances, vaginal
medications, suppositories, feminine sprays, genital
wipes, or contraceptive spermacides for 48 hours prior
to their scheduled visits
Had an infection of the genitals within the past
6 weeks
Had been medically diagnosed as having diabetes,
kidney failure, hepatitis, AIDS (HIV positive) or
toxic shock syndrome
Were currently taking (within the last 30 days)
immunosuppressive drugs, chemotherapy,
systemic antimicrobial drugs, or antifungals or
antimicrobials to treat a vaginal infection
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100. Subjects with carrier indices of 0 - 24% were classi-
fied as transient, between 25 - 74% were classified as
intermittent, and 75 - 100% were considered persistent
carriers. This classification was an arbitrary designation
and was use to simply explain the data.
Results
Demographics of subjects
The geographical distribution of the 311 subjects
enrolled in the study was similar to that for the previous
study [14], except that the percentage of participants
from Arizona, Florida and Manitoba was slightly higher.
The distribution was: Arizona, 24% (n =7 6 ) ;F l o r i d a ,
22% (n = 68); New Jersey 13% (n =4 1 ) ;a n dO h i o ,1 6 %
(n = 50) (United States) and Manitoba, 24% (n =7 6 )
(Canada). The mean age of subjects enrolled in each
group varied between 26.8 and 29.0 years of age. The
ethnic/racial distribution varied between the five groups
as follows: Caucasian: 77 - 90%; Black: 4 - 15%; Hispa-
nic: 0 - 5%; Asian: 0 - 4%.
Persistence of S. aureus carriage
Results in Table 3 show that nasal carriage of S. aureus
is more persistent (35.5% and 41.0% groups 2 and 3)
than vaginal or anal carriage, regardless of the strain.
Vaginal and anal carriage of S. aureus is more transient
(ranging from 55 to 77% of group) than nasal carriage.
Seventeen subjects assigned to Group 4 (the negative
control for S. aureus) were found to be culture-positive
for non-toxigenic S. aureus and four of these showed
persistent carriage.
Persistence of serum antibody to TSST-1
Serum antibody titers distributions from Group 1 and 2
(Figure 1) were found to be skewed toward higher titers
during the follow up study, with the vast majority of visits
showing titers ≥1:64. Carriers of non-toxigenic S. aureus
(Group 3) and non-carriers (Group 4) (Figure 2) contin-
ued to show a broad distribution of antibody titers during
the follow up study with antibody titers ≤ 1:64 at a signif-
icant number of visits. In total, twenty-one subjects in
Groups 3, 4, and 5 became colonized with TSST-1 pro-
ducing S. aureus during the course of the follow up study
either by converting from non-toxigenic S. aureus or by
acquiring a toxigenic S. aureus colony at one of the body
sites. None of these subjects showed symptoms of toxic
shock syndrome. In addition, these subjects were gener-
ally found to have sera anti-TSST-1 antibody distribu-
tions similar to carriers in Groups 1 and 2.
Five subjects from Group 5 seroconverted during the
course of this study. Four subjects seroconverted
between the end of the previous study [14] and the start
of this study (approximately 1 year). One subject sero-
converted between visit #3 and visit #4 of the follow up
study (Table 4). Their ages ranged from 15 to 36, and
none experienced TSS-like symptoms. No evidence of
TSST-1 producing S. aureus was found in the body sites
cultured from the four subjects, but it was detectable in
the subject who converted between visit #3 and visit #4.
This corresponded to the time interval in which serum
anti-TSST-1 antibody titer increased from ≤1:4 to 1:128.
Discussion
Results of this study among healthy, menstruating
women indicate that the distribution of carriage types
vary more by body site than by the type of S. aureus
strain (toxigenic or non-toxigenic). Nasal carriage of
S. aureus appeared to be persistent (41% and 35.5%),
whereas vaginal and anal carriage appeared to be more
transient. Compared to findings from other studies sum-
marized by VandenBergh [27], nasal carriage was more
persistent in this study, which may be due to the fact that
the subjects in these groups were selected based on their
initial S. aureus carriage. A recent article by Nilsson and
Ripa [36] determined the frequency and persistence of
S. aureus colonization in the nose and throat in hospital
patents and staff. These results demonstrated a nasal
carriage rate of 31% and 36%, respectively and a more
frequent S. aureus throat colonization of 46% and 54%.
Table 3 Classification of S. aureus colonization types in subjects completing a minimum of three subsequent visits
Group
No.
Sample
location
S. aureus No. of
subjects
% Transient
carriers (#subjects)
CI
a = 0 -24%
% Intermittent
carriers (#subjects)
CI
a = 25 -74%
% Persistent
carriers (#subjects)
CI
a = 75-100%
1 Vagina Toxigenic 13 76.9% (10) 23.1% (3) 0% (0)
2 Nasal Toxigenic 61 29.5% (18) 29.5% (18) 41.0% (25)
2 Anal Toxigenic 12 66.7% (8) 33.3% (4) 0% (0)
3 Vagina Non-toxigenic 22 54.5% (12) 40.9% (9) 4.5% (1)
3 Nasal Non-toxigenic 31 29.0% (9) 35.5% (11) 35.5% (11)
3 Anal Non-toxigenic 14 64.3% (9) 28.6% (4) 7.1% (1)
4 Any site Non-toxigenic 58 70.7% (41) 22.4% (13) 6.9% (4)
4 Any site Toxigenic 58 94.8% (55) 5.2% (3) 0% (0)
aCI = carrier index, the number of swabs with positive culture of S. aureus relative to the total number of swabs taken × 100
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subsequent S. aureus at other anatomical sites.
The higher persistence of S. aureus nasal carriage may
reflect higher colonization of S. aureus in the nasal
environment than the other body sites. Early experi-
ments suggested that S. aureus binding to mucin may
be critical for colonization of the nasophyngeal mucosa
[37]. It has been suggested that the presence of type I
cytokeratin 10 in the nasal epithelium allows clumping
factor B (clfb) associated with S. aureus to bind to the
epithelium and promote nasal colonization [38].
Another contributing factor to colonization frequency
may be associated with human gene polymorphisms. An
article published in 2006 by van den Akker [39] showed
a clear association between persistent S. aureus nasal
colonization and the glucocorticoid (GC) gene receptor.
Carriers of the GC polymorphism were shown to
increase the risk of persistent S. aureus nasal carriage
by 80%.
The absence of persistent carriage in the vagina may
reflect low colonization due to the lack of type I
cytokeratin 10 in the mucosal epithelium or to changes
in the vaginal environment during the menstrual cycle.
Previous studies of vaginal biopsies using monoclonal
antibodies showed the lack of cytokeratin 10 on the
vaginal epithelium [C. Davis, A Kanti, M. Hansmann, J.
Flood, C. Squier and J. Krueger, Abstr. Intersci. Conf.
Antimicrob. Agents Chemother. abstr. B-1111, 2002].
Changes in the vaginal environment related to the men-
strual cycle, such as levels of iron, O2,C O 2,p H ,h o r -
mones [19-22], could also affect the total number of
bacteria present or the number of colonizing species.
We speculate that the absence of persistent carriage in
the anus may be related to lack of cytokeratin 10 bind-
ing sites (a marker associated with keratinizing cells) in
the columnar epithelium, presence of intestinal mucus,
and/or competition from the large population of micro-
organisms (including lactic acid bacteria) in the human
intestine [40,41].
The distribution of serum antibody titer among Group 1
subjects (Figure 1) was found to remain skewed toward
higher titers during subsequent visits even though the
number of positive culture isolations of toxigenic S. aureus
dropped significantly during this part of the follow up
study. This was also found to be true among Group 2 sub-
jects (Figure 1); however, Group 2 also had a higher level
of reisolation of toxigenic S. aureus during the subsequent
visits. This seems to suggest that colonization at some
point in time is sufficient to elevate antibody titers and
those levels appear to be persistent. Antibody titer distri-
butions among Groups 3 and 4 (Figure 2) showed trends
similar to the original 3012 subjects’ antibody titer
distribution.
Five subjects with no initial serum antibody became
seropositve (titer ≥ 1:32) over the course of the two and
a half year study for a seroconversion rate of 7% of sub-
jects. It is important to note that two of the five subjects
were 18 years of age or younger. In addition, none of
these subjects experienced TSS-like symptoms. These
findings suggest that women can become seropositive at
Figure 1 Anti-TSST-1 antibody titers for Groups 1 & 2.A
histogram of antibody titers expressed as a two-fold serial dilution
starting at 1:4 to ≥ 1024 versus total number of subject visits.
Figure 2 Anti-TSST-1 antibody titers for Groups 3 & 4.A
histogram of antibody titers expressed as a two-fold serial dilution
starting at 1:4 to ≥ 1024 versus total number of subject visits.
Table 4 Antibody titer by visit for subjects in Group 5
that seroconverted
Age of
subject
Ab
a titer previous
study
Ab
a titer during follow
up study
Visit #1 Visit
#2
Visit
#3
Visit
#4
15 ≤1:4 1:512 1:512 1:1024
18 ≤1:4 1:128 1:64 1:64
29 ≤1:4 1:64 1:64 N.C.
b
26 ≤1:4 1:128 1:128 1:512
36 ≤1:4 ≤1:4 ≤1:4 1:128
c
aAnti-TSST-1 antibody.
bNot collected; subject did not return for final visit.
cTSST-1 producing S. aureus isolated from sample taken at this visit.
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a result of environmental exposures that do not result
in TSS-like symptoms.
Conclusions
Nasal carriage of S. aureus appeared to be persistent and
the best predicator of subsequent colonization, whereas
vaginal and anal carriage appeared to be more transient.
I ti si n t e r e s t i n gt h a ta tl e a s t2 9 . 3 %( 1 7 / 5 8 )o fp r e v i o u s
stated as non carriers showed to be positive during the
follow up visits. This reinforces the concept that the car-
rier state for the human is not always absolute and this
has been noted by other investigators [42]. A limitation
of our study is that swab samples were analyzed in sing-
let, so that inter-observer variation in detection of
S. aureus could not be determined; conventional meth-
ods for bacterial isolation and identification were
employed, however, for which reason we are confident
in the quality of our data.
Serum IgG levels against TSST-1 has also been found
to be higher in persistent carriers than in non-carriers
of S. aureus[ 4 2 ] .F r o mt h e s ef i n d i n g s ,i ta p p e a r st h a t
antibody titers in women found to be colonized with
toxigenic S. aureus remained skewed toward higher
titers whether or not the colonies were found to be per-
sistent or transient in nature. This suggests that coloni-
zation at some point in time is sufficient to elevate
antibody titer levels and those levels appear to be persis-
tent. Results also indicate that women can become sero-
positive (7% seroconversion rate) without experiencing
signs or symptoms of toxic shock syndrome.
Colonization of S. aureus TSST-1 and the absence of
antibodies to TSST-1 are important in the pathogenesis
of mTSS. Other factors not studied in the report include
specific V beta 2 TCR (T cell receptor) expansion and
human leukocyte antigen (HLA) haplotype [43,44].
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